– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.